Drug Trial Radar · NCT06775340
Study of RSS0343 Tablets in Patients With Non-cystic Fibrosis Bronchiectasis
Last checked: Nov 19, 2026Latest source record: May 13, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
252
Planned (sponsor's estimate)
Start
Jan 22, 2025
Primary completion
Nov 2027
Study completion Dec 2027
Sponsor
- Lead sponsor
- Jiangsu HengRui Medicine Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jan 15, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Studies to evaluate the safety, tolerability, pharmacodynamics, and efficacy of RSS0343 tablets in patients with non-cystic fibrosis bronchiectasis
Conditions
- Adolescent Asthma
Interventions
RSS0343 TabellaDrug
RSS0343 tablets, oral;
Primary outcomes
What the sponsor says the trial is designed to measure.
- The number of occurrences of AEsTime frame: Day 1 to Day56
- the frequency of occurrence of AEsTime frame: Day 1 to Day56
Locations
1 site in 1 country. Site status is shown where the registry gives one.
First Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.